Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Efavirenz: practicalities, considerations and new issues.

G Moyle1

  • 1Chelsea and Westminster Hospital, London, UK.

International Journal of Clinical Practice. Supplement
|January 6, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impacts of dance on cognition, psychological symptoms and quality of life in Parkinson's disease.

NeuroRehabilitation·2019
Same author

Amprenavir : A Viewpoint by Graeme Moyle.

Drugs·2016
Same author

Low levels of neurocognitive impairment detected in screening HIV-infected men who have sex with men: The MSM Neurocog Study.

International journal of STD & AIDS·2016
Same author

A cross-sectional study to evaluate the association of hyperbilirubinaemia on markers of cardiovascular disease, neurocognitive function, bone mineral density and renal markers in HIV-1 infected subjects on protease inhibitors.

HIV clinical trials·2016
Same author

Screening for chronic comorbid diseases in people with HIV: the need for a strategic approach.

HIV medicine·2012
Same author

Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissue.

HIV clinical trials·2012
Same journal

Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.

International journal of clinical practice. Supplement·2015
Same journal

Efficacy and safety of basiliximab in liver transplantation for patients with hepatitis B virus-related diseases: a single centre study.

International journal of clinical practice. Supplement·2015
Same journal

Human parvovirus B19 infection induced pure red cell aplasia in liver transplant recipients.

International journal of clinical practice. Supplement·2015
Same journal

Interleukin-2 receptor antagonist compared with antithymocyte globulin induction therapy in kidney transplantation from donors after cardiac death.

International journal of clinical practice. Supplement·2015
Same journal

Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.

International journal of clinical practice. Supplement·2015
Same journal

Outcomes of standard dose EC-MPS with low exposure to CsA in DCD renal transplantation recipients with DGF.

International journal of clinical practice. Supplement·2015
See all related articles

Protease inhibitor (PI) therapy is being reevaluated due to safety concerns and the effectiveness of PI-sparing regimens. Efavirenz shows potent and durable antiviral activity in these regimens with good tolerability.

Area of Science:

  • HIV/AIDS research
  • Antiretroviral therapy

Background:

  • Long-term safety concerns with protease inhibitors (PIs) prompt reevaluation of HIV treatment strategies.
  • Emerging non-PI regimens show potent and durable viral suppression, questioning the role of traditional PI therapy.

Purpose of the Study:

  • To investigate the role and efficacy of efavirenz in PI-sparing antiretroviral regimens.
  • To clarify the durability, virologic benefits in sanctuary sites, and immune function changes associated with PI-sparing regimens.

Main Methods:

  • Investigating the role of efavirenz in first-line and salvage PI-sparing regimens.
  • Evaluating antiviral activity, durability, and tolerability of efavirenz-based regimens.

Main Results:

  • Efavirenz demonstrates potent and durable antiviral activity in PI-sparing regimens.

Related Experiment Videos

  • Adverse events associated with efavirenz are generally mild and infrequently lead to discontinuation.

    • Conclusions:

    • Efavirenz is a viable option in PI-sparing regimens for HIV treatment.
    • Further clarification is needed on PI-sparing regimens' long-term durability and immune effects.